MTSR רווח נקי למניה ב-12 החודשים האחרונים metsera.com
Metsera Inc (MTSR) is currently undergoing a phase of high fixed costs for clinical trials prior to its market entry. The development of obesity treatments is accelerating through partnerships with research centers and manufacturers. The rolling revenue per share metric demonstrates that the value is holding at -2.97, highlighting the risks associated with a lack of revenue during the early stages of product creation.
%20%D7%A8%D7%95%D7%95%D7%97%20%D7%9C%D7%9E%D7%A0%D7%99%D7%94%20%D7%91%D7%90%D7%A8%D7%91%D7%A2%D7%AA%20%D7%94%D7%A8%D7%91%D7%A2%D7%95%D7%A0%D7%99%D7%9D%20%D7%94%D7%90%D7%97%D7%A8%D7%95%D7%A0%D7%99%D7%9D&width=1200&height=400&colorIndex=0&v=mwa76aez.ocr-7cpmfb4&start=20220704&end=20261110&filename=GURU_Markets_-_MTSR_-_Metsera-Inc_-_Earnings-per-share-for-the-last-four-quarters "Metsera Corp - רווח נקי למניה (EPS TTM) MTSR (תקופה 01.02.2025 - 29.11.2025) | 👁️GURU.Markets👁️")
פילוחים אנליטיים ודוחות נתונים של חברת Metsera, Inc. (MTSR)
The investment attractiveness of Metsera Inc (MTSR) is based on the development of innovative anti-obesity drugs, which requires significant expenditures on clinical trials. The calculation logic of the TTM net income per share measures the final return on equity over a rolling year, allowing investors to assess the real fundamental value of the security relative to market volatility and determine the degree of the asset's undervaluation.
